Clik here to view.
Aeterna shares tumble after cancer-killing agent fails in Phase III trial
Shares in Aeterna Zentaris (NSDQ:AEZS) fell more than -50% this morning after the company said that the Phase III trial of Zoptrex did not meet its primary endpoint in women with locally advanced,...
View ArticleClik here to view.
Savara inks $15m loan agreement
Savara (NSDQ:SVRA) said today that it inked a $15 million loan agreement with Silicon Valley Bank. According to the deal, Savara can draw $7.5 million from the $15 million debt facility immediately....
View ArticleClik here to view.
Kala touts Phase III data for nanoparticle ophthalmic suspension
Kala Pharmaceuticals touted data today from a Phase III trial of its nanoparticle formulation of loteprednol etabonate as a treatment for inflammation and pain in cataract surgery patients. The KPI-121...
View ArticleClik here to view.
Advanced Proteome Therapeutics moves into Johnson & Johnson’s Innovation lab
Credit: JLabs @ Toronto Boston-based biotech Advanced Proteome Therapeutics (CVE:APC) said today that it is moving into Johnson & Johnson‘s (NYSE:JNJ) Innovation lab, JLabs, in Toronto. The 40,000...
View ArticleClik here to view.
scPharmaceuticals names Tucker as CEO | Personnel Moves – May 1, 2017
scPharmaceuticals said in late April that it named pharma-veteran John Tucker as president & CEO, effective immediately. Tucker was also elected to the company’s board of directors. Tucker formerly...
View ArticleClik here to view.
Digital health start-up Amalgam Rx launches with insulin titration app
Digital health start-up Amalgam Rx launched today with the release of iSage Rx, which it touts as the 1st FDA 510(k)-cleared, prescription mobile app for insulin titration. The app allows physicians to...
View ArticleClik here to view.
Lyndra gets boost for drug delivery platform from U.S. allergy institute
Lyndra said today that it won a 5-year grant from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health. The grant is slated to support the...
View ArticleClik here to view.
Magenta raises $50m, inks partnership with Novartis for stem cell transplant...
Magenta Therapeutics said today that it closed a $50 million Series B round and licensed a clinical-stage program from Novartis (NYSE:NVS) to advance its stem cell transplantation platform. The company...
View ArticleClik here to view.
Braeburn, Camurus tout long-term phase III data for opioid addiction therapy
Braeburn Pharmaceuticals and Camurus (STO:CAMX) touted data today from a long-term Phase III study of its weekly and monthly buprenorphine depots in patients with moderate-to-severe opioid use...
View ArticleClik here to view.
FDA OKs BioDelivery Sciences’ Bunavail opioid dependence film
BioDelivery Sciences International (NSDQ:BDSI) said today that the FDA approved a supplemental new drug application for its Bunavail buprenorphine and naloxone buccal film. The revised indication...
View ArticleClik here to view.
Pfizer posts mixed Q1 results
Shares in Pfizer (NYSE:PFE) fell today after the pharma giant missed sales expectations, but beat earnings estimates on Wall Street with its 1st quarter results. The N.Y.-based company posted profits...
View ArticleClik here to view.
Intersect ENT beats Q1 earnings, rev forecast
Shares in Intersect ENT (NSDQ:XENT) fell slightly yesterday after the drug-device maker met expectations on Wall Street with its 1st quarter results. The Menlo Park, Calif.-based company posted a loss...
View ArticleClik here to view.
Nordisk shares climb after Q1 beat
Shares in Novo Nordisk (NYSE:NVO) rose today after the insulin-maker met expectations on Wall Street with its 1st quarter results. The Denmark-based company posted profits of $1.49 billion, or 60¢ per...
View ArticleClik here to view.
Pieris, AstraZeneca ink $45m deal for inhaled respiratory drugs
Pieris Pharmaceuticals (NSDQ:PIRS) inked a $45 million deal with AstraZeneca (NYSE:AZN) to develop a group of inhaled drugs for respiratory diseases. According to the deal, Pieris will get $45 million...
View ArticleClik here to view.
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide...
View ArticleClik here to view.
Regeneron posts mixed Q1 results, Eylea growth slows
Shares in Regeneron (NSDQ:REGN) rose today after the company beat revenue expectations on The Street with its 1st quarter financial results. The company’s total sales rose to $1.32 billion, exceeding...
View ArticleClik here to view.
New medicines could eliminate uterine fibroid surgeries
[Image from the U.S. Department of Health and Human Services]Decisions Resources Group, a healthcare research and data company, suggests that the launch of new medicines could be a long-term management...
View ArticleClik here to view.
FDA approves first ALS treatment in over 2 decades
The FDA recently announced that it has approved the drug Radicava (edaravone) to help treat patients who have amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a...
View ArticleClik here to view.
Novocure touts quality of life data for Optune, chemo combo
Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed...
View ArticleClik here to view.
Nanoscale ‘slingshot’ shoots drug to infection site
Researchers from the University of Rome Tor Vergata and the University of Montreal have reported the design and synthesis of a nanoscale molecular slingshot made of DNA that could potentially shoot and...
View Article